You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (3) |
Back to Search
The efficacy and safety of zepatier treatment experience in hcv genotype 1 patients
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-HPS-043
- By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Department of pharmacy)
- Co-author(s): Tzu-Cheng Tsai
Shin-Tarng Deng
Chao-Wei Hsu - Abstract:
Background
Zepatier (elbasvir and grazoprevir) is a directly acting antivirals (DAA) for treatment of chronic HCV genotype (GT) 1 or 4 infection in adults. It was approved by TFDA since Dec. 2016, then reimbursement for fibrosis 3 or 4 (F3 or 4) by NHI since Aug. 2017. Approximately 53% of HCV infected patients were genotype 1 in Taiwan, DAA was.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026